Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
ChromaDex partners with MyPharma2Go for sales of Tru Niagen in Brazil » 06:34
09/01/22
09/01
06:34
09/01/22
06:34
CDXC

ChromaDex

$1.44 /

+0.04 (+2.86%)

ChromaDex announced a…

ChromaDex announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen, is the world's most efficient nicotinamide adenine dinucleotide precursor on the market, particularly over NMN. MyPharma2Go, an American company focused on Brazil and Latin America, developed a cross-border e-commerce platform that allows patients to have direct access to international medicines and supplements, and monitors the international shipping process from origin to delivery.

ShowHide Related Items >><<
CDXC ChromaDex
$1.44 /

+0.04 (+2.86%)

CDXC ChromaDex
$1.44 /

+0.04 (+2.86%)

08/29/22 H.C. Wainwright
ChromaDex price target lowered to $5.50 from $7 at H.C. Wainwright
08/16/22 Oppenheimer
Oppenheimer downgrades ChromaDex to Perform as top line likely to remain subdued
08/16/22 Oppenheimer
ChromaDex downgraded to Perform from Outperform at Oppenheimer
08/11/22 B. Riley
ChromaDex downgraded to Neutral from Buy at B. Riley
CDXC ChromaDex
$1.44 /

+0.04 (+2.86%)

Recommendations
ChromaDex price target lowered to $5.50 from $7 at H.C. Wainwright » 06:07
08/29/22
08/29
06:07
08/29/22
06:07
CDXC

ChromaDex

$1.48 /

-0.1 (-6.33%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on ChromaDex to $5.50 from $7 and keeps a Buy rating on the shares. The company's revamped strategy should reduce expenses, but its revenue growth is likely to be slower than expected, Selvaraju tells investors in a research note.

ShowHide Related Items >><<
CDXC ChromaDex
$1.48 /

-0.1 (-6.33%)

CDXC ChromaDex
$1.48 /

-0.1 (-6.33%)

08/16/22 Oppenheimer
Oppenheimer downgrades ChromaDex to Perform as top line likely to remain subdued
08/16/22 Oppenheimer
ChromaDex downgraded to Perform from Outperform at Oppenheimer
08/11/22 B. Riley
ChromaDex downgraded to Neutral from Buy at B. Riley
06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
CDXC ChromaDex
$1.48 /

-0.1 (-6.33%)

Downgrade
Oppenheimer downgrades ChromaDex to Perform as top line likely to remain subdued » 06:05
08/16/22
08/16
06:05
08/16/22
06:05
CDXC

ChromaDex

$1.75 /

+0.06 (+3.55%)

As previously reported,…

As previously reported, Oppenheimer analyst Brian Nagel downgraded ChromaDex to Perform from Outperform. The analyst remains upbeat upon underlying prospects for Tru Niagen, its NAD boosting and anti-aging supplement, and the exhaustive science supporting the product. That said, Nagel is now increasingly concerned that in the absence of a much more significant commitment to marketing and brand building on the part of ChromaDex, sales of Tru Niagen are likely to continue to languish, particularly amongst more mass market consumers. He awaits clearer signals of improving, sustained top-line trends at ChromaDex, before again turning more positive on shares.

ShowHide Related Items >><<
CDXC ChromaDex
$1.75 /

+0.06 (+3.55%)

CDXC ChromaDex
$1.75 /

+0.06 (+3.55%)

08/16/22 Oppenheimer
ChromaDex downgraded to Perform from Outperform at Oppenheimer
08/11/22 B. Riley
ChromaDex downgraded to Neutral from Buy at B. Riley
06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
CDXC ChromaDex
$1.75 /

+0.06 (+3.55%)

Downgrade
ChromaDex downgraded to Perform from Outperform at Oppenheimer » 05:41
08/16/22
08/16
05:41
08/16/22
05:41
CDXC

ChromaDex

$1.75 /

+0.06 (+3.55%)

Oppenheimer analyst Brian…

Oppenheimer analyst Brian Nagel downgraded ChromaDex to Perform from Outperform.

ShowHide Related Items >><<
CDXC ChromaDex
$1.75 /

+0.06 (+3.55%)

CDXC ChromaDex
$1.75 /

+0.06 (+3.55%)

08/11/22 B. Riley
ChromaDex downgraded to Neutral from Buy at B. Riley
06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
04/18/22 H.C. Wainwright
ChromaDex price target lowered to $8 from $12 at H.C. Wainwright
CDXC ChromaDex
$1.75 /

+0.06 (+3.55%)

Hot Stocks
ChromaDex's license for NR patent upheld in challenge by Thorne » 06:44
08/15/22
08/15
06:44
08/15/22
06:44
CDXC

ChromaDex

$1.69 /

+0.04 (+2.42%)

, THRN

Thorne HealthTech

$5.27 /

-0.04 (-0.75%)

ChromaDex announced the…

ChromaDex announced the USPTO's Patent Trial and Appeal Board's decision to reject Thorne Research's attempt to invalidate U.S. Patent No. 8,197,807. ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research from raising these arguments, or any other arguments they could have reasonably raised before the PTAB in the New York District Court lawsuit ChromaDex brought against Thorne Research wherein ChromaDex alleges Thorne Research is infringing the 807 patent. ChromaDex is the exclusive supplier of nicotinamide riboside chloride, Niagen, a novel form of NR. ChromaDex maintains a growing intellectual property portfolio for its proprietary ingredient, Niagen.

ShowHide Related Items >><<
THRN Thorne HealthTech
$5.27 /

-0.04 (-0.75%)

CDXC ChromaDex
$1.69 /

+0.04 (+2.42%)

CDXC ChromaDex
$1.69 /

+0.04 (+2.42%)

08/11/22 B. Riley
ChromaDex downgraded to Neutral from Buy at B. Riley
06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
04/18/22 H.C. Wainwright
ChromaDex price target lowered to $8 from $12 at H.C. Wainwright
THRN Thorne HealthTech
$5.27 /

-0.04 (-0.75%)

08/11/22 Cowen
Thorne HealthTech price target lowered to $8 from $12 at Cowen
10/18/21 BofA
Thorne HealthTech initiated with a Buy at BofA
10/18/21 BofA
Thorne HealthTech initiated with a Buy at BofA
10/18/21 Cowen
Cowen starts Thorne HealthTech at Outperform with $11 price target
THRN Thorne HealthTech
$5.27 /

-0.04 (-0.75%)

CDXC ChromaDex
$1.69 /

+0.04 (+2.42%)

  • 23
    Sep
THRN Thorne HealthTech
$5.27 /

-0.04 (-0.75%)

Hot Stocks
ChromaDex reports CFO Kevin Farr terminated without cause » 08:15
08/11/22
08/11
08:15
08/11/22
08:15
CDXC

ChromaDex

$2.08 /

+0.155 (+8.05%)

In a regulatory filing…

In a regulatory filing last night, ChromaDex disclosed that on August 10, Kevin Farr was terminated without cause as Chief Financial Officer of the company, and as an officer, employee, and director of the company and any subsidiaries of the company in which he serves in any of those capacities, effective as of August 12. Also on August 10, the board of directors of ChromaDex appointed Brianna Gerber as SVP, Finance / Interim Chief Financial Officer, effective as of August 11, to replace the vacancy created by Farr's termination. Gerber previously served as Vice President of Finance and Investor Relations of ChromaDex since September 17, 2018, and prior to that served in multiple leadership roles at Mattel (MAT) since 2013, the filing noted.

ShowHide Related Items >><<
CDXC ChromaDex
$2.08 /

+0.155 (+8.05%)

CDXC ChromaDex
$2.08 /

+0.155 (+8.05%)

08/11/22 B. Riley
ChromaDex downgraded to Neutral from Buy at B. Riley
06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
04/18/22 H.C. Wainwright
ChromaDex price target lowered to $8 from $12 at H.C. Wainwright
CDXC ChromaDex
$2.08 /

+0.155 (+8.05%)

Downgrade
ChromaDex downgraded to Neutral from Buy at B. Riley » 08:12
08/11/22
08/11
08:12
08/11/22
08:12
CDXC

ChromaDex

$2.08 /

+0.155 (+8.05%)

B. Riley analyst Jeff Van…

B. Riley analyst Jeff Van Sinderen downgraded ChromaDex to Neutral from Buy with a price target of $2.40, down from $6, after the company reported Q2 sales and AEBITDA below his and consensus expectations and lowered FY22 revenue and gross margin guidance. In addition, ChromaDex announced the termination without cause of the CFO Kevin Farr along with the appointment of an interim CFO.

ShowHide Related Items >><<
CDXC ChromaDex
$2.08 /

+0.155 (+8.05%)

CDXC ChromaDex
$2.08 /

+0.155 (+8.05%)

06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
04/18/22 H.C. Wainwright
ChromaDex price target lowered to $8 from $12 at H.C. Wainwright
03/10/22 B. Riley
ChromaDex price target lowered to $8 from $16 at B. Riley
CDXC ChromaDex
$2.08 /

+0.155 (+8.05%)

Earnings
ChromaDex sees FY22 revenue growth high single digits, consensus $76.68M » 16:03
08/10/22
08/10
16:03
08/10/22
16:03
CDXC

ChromaDex

$2.07 /

+0.14 (+7.27%)

Looking forward, for the…

Looking forward, for the full year, the Company expects high single digit revenue growth, driven by its global e-commerce business, offset by slower growth with new, and existing, partners. For the full year, the Company expects approximately 60% gross margin, selling and marketing expense will be down as a percentage of net sales, approximately $1 million increase in R&D, and approximately $6 to 7 million decrease in general and administrative expense, as reported, driven by lower legal expense. The Company expects to approach cash flow break-even in the third quarter and be cash flow break-even or better in the fourth quarter of 2022. The Company considers Adjusted EBITDA including legal expense, a non-GAAP metric, to be a proxy for cash flow before working capital investments, and is targeting cash flow break-even on that basis.

ShowHide Related Items >><<
CDXC ChromaDex
$2.07 /

+0.14 (+7.27%)

CDXC ChromaDex
$2.07 /

+0.14 (+7.27%)

06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
04/18/22 H.C. Wainwright
ChromaDex price target lowered to $8 from $12 at H.C. Wainwright
03/10/22 B. Riley
ChromaDex price target lowered to $8 from $16 at B. Riley
CDXC ChromaDex
$2.07 /

+0.14 (+7.27%)

Earnings
ChromaDex reports Q2 EPS (9c), consensus (8c) » 16:03
08/10/22
08/10
16:03
08/10/22
16:03
CDXC

ChromaDex

$2.07 /

+0.14 (+7.27%)

Reports Q2 revenue…

Reports Q2 revenue $16.7M, consensus $18.65M. "Our team is doing great work in a challenging environment," said CEO Rob Fried. "The e-commerce business continues to grow, and we are excited about our new partnerships in China and South Korea. We are placing greater emphasis on operating efficiency and profitable growth in the second half of the year."

ShowHide Related Items >><<
CDXC ChromaDex
$2.07 /

+0.14 (+7.27%)

CDXC ChromaDex
$2.07 /

+0.14 (+7.27%)

06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
04/18/22 H.C. Wainwright
ChromaDex price target lowered to $8 from $12 at H.C. Wainwright
03/10/22 B. Riley
ChromaDex price target lowered to $8 from $16 at B. Riley
CDXC ChromaDex
$2.07 /

+0.14 (+7.27%)

Conference/Events
ChromaDex to hold a key opinion leader webinar » 10:39
07/20/22
07/20
10:39
07/20/22
10:39
CDXC

ChromaDex

$1.87 /

+0.18 (+10.68%)

Management holds a Key…

Management holds a Key Opinion Leader Webinar entitled, "Transforming Benefits of Nicotinamide Riboside (NR)" with Dr. Brenner, Alfred E Mann Family Foundation Chair in Diabetes & Cancer Metabolism at City of Hope National Medical Center on July 20 at 11 am. Webcast Link

ShowHide Related Items >><<
CDXC ChromaDex
$1.87 /

+0.18 (+10.68%)

CDXC ChromaDex
$1.87 /

+0.18 (+10.68%)

06/07/22 H.C. Wainwright
ChromaDex price target lowered to $7 from $8 at H.C. Wainwright
05/13/22 B. Riley
ChromaDex price target lowered to $6 from $8 at B. Riley
04/18/22 H.C. Wainwright
ChromaDex price target lowered to $8 from $12 at H.C. Wainwright
03/10/22 B. Riley
ChromaDex price target lowered to $8 from $16 at B. Riley
CDXC ChromaDex
$1.87 /

+0.18 (+10.68%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.